These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 14991124)
41. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active. Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193 [No Abstract] [Full Text] [Related]
42. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Doggrell S Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346 [TBL] [Abstract][Full Text] [Related]
43. Management of erectile dysfunction in general practice. De Berardis G; Pellegrini F; Franciosi M; Pamparana F; Morelli P; Tognoni G; Nicolucci A J Sex Med; 2009 Apr; 6(4):1127-1134. PubMed ID: 19138378 [TBL] [Abstract][Full Text] [Related]
45. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. Montorsi F; Corbin J; Phillips S J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964 [TBL] [Abstract][Full Text] [Related]
46. [Vardenafil for refractory erectile dysfunction: the latest advances]. Wang HY; Huang YF Zhonghua Nan Ke Xue; 2009 Nov; 15(11):1035-8. PubMed ID: 20218319 [TBL] [Abstract][Full Text] [Related]
47. Management of male erectile dysfunction: a review. Magoha GA East Afr Med J; 1998 Nov; 75(11):623-7. PubMed ID: 10065171 [TBL] [Abstract][Full Text] [Related]
48. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A; Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306 [TBL] [Abstract][Full Text] [Related]
49. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324 [TBL] [Abstract][Full Text] [Related]
51. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Kloner RA Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876 [No Abstract] [Full Text] [Related]
52. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. Ljunggren C; Hedelin H; Salomonsson K; Ströberg P J Sex Med; 2008 Feb; 5(2):469-75. PubMed ID: 18086159 [TBL] [Abstract][Full Text] [Related]
53. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors. Tsai WK; Jiann BP Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166 [TBL] [Abstract][Full Text] [Related]
55. Non-surgical management of erectile dysfunction. Levy A; Crowley T; Gingell C Clin Endocrinol (Oxf); 2000 Mar; 52(3):253-60. PubMed ID: 10718821 [TBL] [Abstract][Full Text] [Related]
56. Viagra for depression. Harv Ment Health Lett; 2002 Feb; 18(8):7. PubMed ID: 11869980 [No Abstract] [Full Text] [Related]
57. Use of sildenafil in penile implant patients. Mireku-Boateng AO; Dennery M; Littlejohn J Urol Int; 2001; 66(3):149-51. PubMed ID: 11316977 [TBL] [Abstract][Full Text] [Related]
58. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Ali ST Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424 [TBL] [Abstract][Full Text] [Related]
60. Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. Tan HL Pharmacoeconomics; 2000 Jan; 17(1):77-107. PubMed ID: 10747767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]